Caricamento...

Do BRAF inhibitors select for populations with different disease progression kinetics?

Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experience a very rapid progression of disease. Such selectivity for more rapid disease progressio...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ascierto, Paolo Antonio, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2013
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3599508/
https://ncbi.nlm.nih.gov/pubmed/23497384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-61
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !